Why this research matters
Stargardt disease is a juvenile-onset inherited retinal dystrophy in which vision loss results from progressive damage to the retina. A central feature of the disease is the buildup of lipofuscin in the retinal pigment epithelium (RPE), a layer of cells that supports the light-sensing photoreceptors. Over time, these deposits can contribute to photoreceptor degeneration and worsening vision.
There are currently no FDA-approved treatments for Stargardt disease. For people and families living with the condition, research aimed at slowing or stopping the biological processes that drive retinal damage is therefore especially important. A 2026 bioRxiv preprint reports encouraging preclinical findings for AKR-XI-85, a small-molecule compound designed to reduce the supply of vitamin A–derived material that contributes to toxic lipofuscin formation.
The biological target: RBP4
The visual cycle is the series of chemical steps that allows the eye to respond to light. Retinol, a form of vitamin A, is needed for this process and travels from the bloodstream to the eye. However, visual-cycle activity also produces bisretinoids—molecules that are major toxic components of lipofuscin.
In Stargardt disease, the accumulation of these compounds in the RPE is particularly harmful. One important bisretinoid is A2E, which is widely used as a marker of lipofuscin buildup in research models.
The new study focuses on retinol-binding protein 4, or RBP4. RBP4 is the key transporter that carries retinol in the bloodstream. For retinol to be efficiently delivered to tissues, RBP4 interacts with another blood protein called transthyretin (TTR). The research team’s strategy was not to eliminate retinol entirely, but to interfere selectively with the RBP4-TTR interaction. By doing so, they aimed to lower the overall retinol load reaching the retina and, in turn, reduce production of damaging bisretinoids.
AKR-XI-85: a non-retinoid RBP4 antagonist
AKR-XI-85 is described as a non-retinoid triazolopyrimidine RBP4 antagonist. “Non-retinoid” is a meaningful feature because the compound is not itself a vitamin A–like molecule. Instead, it is designed to act on RBP4, disrupting formation of the TTR-RBP4-retinol complex that supports retinol transport in blood.
The investigators had previously developed several groups of RBP4 antagonists that could block this protein interaction and lower retinol delivery to the retina. Some earlier chemical types, however, showed off-target activity—effects on biological targets beyond the intended one—that required additional optimization.
According to the preprint, AKR-XI-85 and related compounds showed strong activity in laboratory and animal testing, along with desirable pharmacokinetic properties. Pharmacokinetics describes how a drug is absorbed, distributed, and maintained in the body over time. Importantly, the authors report that AKR-XI-85 did not show limiting off-target activity in their characterization studies.
A substantial reduction in A2E in a Stargardt mouse model
The most notable result came from chronic dosing studies in Abca4 -/- mice. These animals lack both copies of the Abca4 gene and are commonly used to study mechanisms relevant to Stargardt disease, which is most often associated with disease-causing variants in ABCA4.
In these mice, chronic treatment with AKR-XI-85 produced a prolonged reduction in serum RBP4 levels. This is consistent with the compound acting on its intended biological pathway. The treatment also led to a dramatic 70% reduction in A2E accumulation.
This finding is significant because A2E is a critical component of toxic lipofuscin. Reducing its buildup addresses a core disease mechanism rather than only attempting to manage downstream consequences of retinal injury. The result supports the idea that controlling retinol transport may help limit the formation of harmful visual-cycle byproducts in the RPE.
What this could mean for treatment development
This research represents a potential treatment approach based on disease biology: reduce the materials needed to form toxic bisretinoids, with the goal of slowing lipofuscin accumulation and retinal degeneration. If this approach can be successfully developed further, an oral or systemic small-molecule medicine targeting RBP4 could complement the broader Stargardt therapeutic landscape.
The work is also relevant beyond Stargardt disease. The authors note that AKR-XI-85 may have potential in other lipofuscin-dependent retinopathies, conditions in which harmful lipofuscin-related compounds contribute to retinal damage.
At the same time, the reported findings are from preclinical studies in laboratory systems and mice. The next stages of development will need to establish how this candidate performs in further safety, dosing, and human studies, as well as whether lowering RBP4 and A2E ultimately preserves retinal structure and vision.
Looking ahead
The AKR-XI-85 findings add momentum to a growing effort to develop treatments for Stargardt disease that intervene before toxic retinal deposits accumulate. By targeting RBP4, researchers are exploring a way to adjust retinol delivery upstream of bisretinoid production.
For the Stargardt community, this study highlights an important shift in the field: the search for therapies is expanding beyond a single strategy and increasingly includes precisely designed small molecules that target the visual cycle and lipofuscin biology. Continued research will determine whether this promising RBP4 antagonist can advance from a preclinical candidate into a future treatment option for people affected by Stargardt disease.